ArticleJournal of oncology2020

Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Liuwen Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.